

Patrizio Giacomini

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/530736/patrizio-giacomini-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

111
papers

2,997
citations

29
h-index

50
g-index

118
ext. papers

3,266
ext. citations

6.9
avg, IF

4.2
L-index

#	Paper	IF	Citations
111	Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer. <i>Molecular Cancer</i> , 2021 , 20, 151	42.1	1
110	Optical multiplexed bioassays on photonic crystals for breast cancer biomarker detection. <i>EPJ Web of Conferences</i> , 2021 , 255, 13003	0.3	
109	Precision Medicine and Melanoma: Multi-Omics Approaches to Monitoring the Immunotherapy Response. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	6
108	Detection of Tumor DNA in Human Plasma with a Functional PLL-Based Surface Layer and Plasmonic Biosensing. <i>ACS Sensors</i> , 2021 , 6, 2307-2319	9.2	5
107	High activity and low toxicity of a novel CD71-targeting nanotherapeutic named The-0504 on preclinical models of several human aggressive tumors. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021 , 40, 63	12.8	4
106	Direct plasmonic detection of circulating RAS mutated DNA in colorectal cancer patients. <i>Biosensors and Bioelectronics</i> , 2020 , 170, 112648	11.8	13
105	A Distinctive microRNA (miRNA) Signature in the Blood of Colorectal Cancer (CRC) Patients at Surgery. <i>Cancers</i> , 2020 , 12,	6.6	18
104	Bioassay engineering: a combined label-free and fluorescence approach to optimize HER2 detection in complex biological media. <i>Analytical and Bioanalytical Chemistry</i> , 2020 , 412, 3509-3517	4.4	5
103	Cross-sectional analysis of circulating tumor DNA in primary colorectal cancer at surgery and during post-surgery follow-up by liquid biopsy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020 , 39, 69	12.8	9
102	Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018 , 37, 47	12.8	38
101	Liquid biopsy and PCR-free ultrasensitive detection systems in oncology (Review). <i>International Journal of Oncology</i> , 2018 , 53, 1395-1434	4.4	34
100	Liquid biopsy in mice bearing colorectal carcinoma xenografts: gateways regulating the levels of circulating tumor DNA (ctDNA) and miRNA (ctmiRNA). <i>Journal of Experimental and Clinical Cancer Research</i> , 2018 , 37, 124	12.8	18
99	Precision diagnostics of EwingB sarcoma by liquid biopsy: circulating fusion transcripts. <i>Therapeutic Advances in Medical Oncology</i> , 2018 , 10, 1758835918774337	5.4	22
98	Detection of soluble ERBB2 in breast cancer cell lysates using a combined label-free/fluorescence platform based on Bloch surface waves. <i>Biosensors and Bioelectronics</i> , 2017 , 92, 125-130	11.8	27
97	Bloch Surface Waves Biosensors for High Sensitivity Detection of Soluble ERBB2 in a Complex Biological Environment. <i>Biosensors</i> , 2017 , 7,	5.9	6
96	Molecular Immunoavoidance Strategies Targeting Antigen Processing and Presentation 2016 , 279-296		
95	Improved Doxorubicin Encapsulation and Pharmacokinetics of Ferritin-Fusion Protein Nanocarriers Bearing Proline, Serine, and Alanine Elements. <i>Biomacromolecules</i> , 2016 , 17, 514-22	6.9	67

94	Selective delivery of doxorubicin by novel stimuli-sensitive nano-ferritins overcomes tumor refractoriness. <i>Journal of Controlled Release</i> , 2016 , 239, 10-8	11.7	46
93	Up-regulation of activating and inhibitory NKG2 receptors in allogeneic and autologous hematopoietic stem cell grafts. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015 , 34, 98	12.8	12
92	Monoclonal antibodies to HLA-E bind epitopes carried by unfolded μ m-free heavy chains. <i>European Journal of Immunology</i> , 2015 , 45, 2356-64	6.1	8
91	Sub-apoptotic dosages of pro-oxidant vitamin cocktails sensitize human melanoma cells to NK cell lysis. <i>Oncotarget</i> , 2015 , 6, 31039-49	3.3	11
90	A melanoma immune response signature including Human Leukocyte Antigen-E. <i>Pigment Cell and Melanoma Research</i> , 2014 , 27, 103-12	4.5	18
89	Comment on "Influence of HLA-C expression level on HIV control". <i>Science</i> , 2013 , 341, 1175	33.3	5
88	Antibody-drug conjugates: targeting melanoma with cisplatin encapsulated in protein-cage nanoparticles based on human ferritin. <i>Nanoscale</i> , 2013 , 5, 12278-85	7.7	103
87	Programmable interactions of functionalized single bioparticles in a dielectrophoresis-based microarray chip. <i>Analytical Chemistry</i> , 2013 , 85, 8219-24	7.8	28
86	Lysis-on-chip of single target cells following forced interaction with CTLs or NK cells on a dielectrophoresis-based array. <i>Journal of Immunology</i> , 2013 , 191, 3545-52	5.3	15
85	Melanoma molecular classes and prognosis in the postgenomic era. <i>Lancet Oncology, The</i> , 2012 , 13, e205-11	21.7	27
84	Major histocompatibility complex class i and tumour immuno-evasion: how to fool T cells and natural killer cells at one time. <i>Current Oncology</i> , 2012 , 19, 39-41	2.8	29
83	IRF1 and NF-kB restore MHC class I-restricted tumor antigen processing and presentation to cytotoxic T cells in aggressive neuroblastoma. <i>PLoS ONE</i> , 2012 , 7, e46928	3.7	43
82	Human leukocyte antigen E contributes to protect tumor cells from lysis by natural killer cells. <i>Neoplasia</i> , 2011 , 13, 822-30	6.4	60
81	Unknown primary tumors. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2011 , 1816, 13-24	11.2	15
80	High expression of HLA-E in colorectal carcinoma is associated with a favorable prognosis. <i>Journal of Translational Medicine</i> , 2011 , 9, 184	8.5	45
79	Natural killer cells efficiently reject lymphoma silenced for the endoplasmic reticulum aminopeptidase associated with antigen processing. <i>Cancer Research</i> , 2011 , 71, 1597-606	10.1	58
78	NF-kappaB, and not MYCN, regulates MHC class I and endoplasmic reticulum aminopeptidases in human neuroblastoma cells. <i>Cancer Research</i> , 2010 , 70, 916-24	10.1	47
77	Gene variants associated to malignant thyroid disease in familial adenomatous polyposis: a novel APC germline mutation. <i>Journal of Endocrinological Investigation</i> , 2010 , 33, 603-6	5.2	11

76	HLA-E and the origin of immunogenic self HLA epitopes. <i>Molecular Immunology</i> , 2010 , 47, 1661-2; author reply 1163-4	4.3	5
75	Class I HLA folding and antigen presentation in beta 2-microglobulin-defective Daudi cells. <i>Journal of Immunology</i> , 2009 , 182, 3609-17	5.3	18
74	Prognostic factors influencing tumor response, locoregional control and survival, in melanoma patients with multiple limb in-transit metastases treated with TNFalpha-based isolated limb perfusion. <i>In Vivo</i> , 2009 , 23, 347-52	2.3	14
73	N-linked glycosylation selectively regulates the generic folding of HLA-Cw1. <i>Journal of Biological Chemistry</i> , 2008 , 283, 16469-76	5.4	6
72	HLA-E: strong association with beta2-microglobulin and surface expression in the absence of HLA class I signal sequence-derived peptides. <i>Journal of Immunology</i> , 2008 , 181, 5442-50	5.3	29
71	A single bottleneck in HLA-C assembly. <i>Journal of Biological Chemistry</i> , 2008 , 283, 1267-1274	5.4	30
70	Altered expression of endoplasmic reticulum aminopeptidases ERAP1 and ERAP2 in transformed non-lymphoid human tissues. <i>Journal of Cellular Physiology</i> , 2008 , 216, 742-9	7	73
69	Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. <i>PLoS ONE</i> , 2008 , 3, e2236	3.7	312
68	HLA-A, -B, -C expression in colon carcinoma mimics that of the normal colonic mucosa and is prognostically relevant. <i>American Journal of Surgical Pathology</i> , 2007 , 31, 76-84	6.7	21
67	cDNA-array profiling of melanomas and paired melanocyte cultures. <i>Journal of Cellular Physiology</i> , 2006 , 207, 697-705	7	20
66	Expression of endoplasmic reticulum aminopeptidases in EBV-B cell lines from healthy donors and in leukemia/lymphoma, carcinoma, and melanoma cell lines. <i>Journal of Immunology</i> , 2006 , 176, 4869-79	5.3	77
65	Functional expression of a single-chain antibody to ErbB-2 in plants and cell-free systems. <i>Journal of Translational Medicine</i> , 2006 , 4, 39	8.5	22
64	Functional expression of a single-chain antibody specific for the HER2 human oncogene in a bacterial reducing environment. <i>Protein Expression and Purification</i> , 2005 , 44, 10-5	2	16
63	Expression of single-chain antibodies in transgenic plants. <i>Vaccine</i> , 2005 , 23, 1823-7	4.1	31
62	Impaired assembly results in the accumulation of multiple HLA-C heavy chain folding intermediates. <i>Journal of Immunology</i> , 2005 , 175, 6651-8	5.3	10
61	Modular usage of the HLA-DRA promoter in extra-hematopoietic and hematopoietic cell types of transgenic mice. <i>FEBS Journal</i> , 2005 , 272, 3214-26	5.7	4
60	Identification of a novel DNase I hypersensitive site within the far upstream region of the human HLA-DRA gene. <i>International Journal of Molecular Medicine</i> , 2003 , 12, 929	4.4	
59	The antigen processing machinery of class I human leukocyte antigens: linked patterns of gene expression in neoplastic cells. <i>Cancer Research</i> , 2003 , 63, 4119-27	10.1	26

58	An ID card for tumour cell lines: HLA typing can help. <i>Lancet Oncology, The</i> , 2001 , 2, 658	21.7	9
57	Melanomas and melanoma cell lines do not express HLA-G, and the expression cannot be induced by gammaIFN treatment. <i>Tissue Antigens</i> , 2000 , 56, 30-7		41
56	Characterization of a major histocompatibility complex class II X-box-binding protein enhancing tat-induced transcription directed by the human immunodeficiency virus type 1 long terminal repeat. <i>Journal of Virology</i> , 2000 , 74, 8989-9001	6.6	6
55	Biosynthesis of HLA-C heavy chains in melanoma cells with multiple defects in the expression of HLA-A, -B, -C molecules. <i>British Journal of Cancer</i> , 1999 , 80, 639-49	8.7	17
54	Analysis of the human HLA-DRA gene upstream region: evidence for a stem-loop array directed by nuclear factors. <i>Biochimie</i> , 1999 , 81, 219-28	4.6	3
53	HLA-A, -B, -C genotyping and expression in human nonlymphoid tumor cell lines. <i>Journal of Immunotherapy</i> , 1999 , 22, 7-15	5	3
52	Conformation and surface expression of free HLA-CW1 heavy chains in the absence of beta 2-microglobulin. <i>Human Immunology</i> , 1997 , 53, 23-33	2.3	17
51	HLA-C heavy chains free of beta2-microglobulin: distribution in normal tissues and neoplastic lesions of non-lymphoid origin and interferon-gamma responsiveness. <i>Tissue Antigens</i> , 1997 , 50, 555-66		32
50	Distinctive features of the alpha 1-domain alpha helix of HLA-C heavy chains free of beta 2-microglobulin. <i>Human Immunology</i> , 1996 , 46, 69-81	2.3	58
49	Membrane expression of HLA-Cw4 free chains in activated T cells of transgenic mice. <i>Immunogenetics</i> , 1995 , 42, 368-75	3.2	11
48	Sequencing of an upstream region of the human HLA-DRA gene containing X _R and Y _R boxes. <i>Nucleic Acids Research</i> , 1995 , 23, 1671-8	20.1	9
47	DR alpha: E beta heterodimers in DRA transgenic mice hinder expression of E alpha: E beta molecules and are more efficient in antigen presentation. <i>International Immunology</i> , 1995 , 7, 1927-38	4.9	7
46	Binding of Epstein-Barr virus nuclear antigen 1 to DNA: inhibition by distamycin and two novel distamycin analogues. <i>European Journal of Pharmacology</i> , 1994 , 267, 143-9		20
45	Distamycin analogues with improved sequence-specific DNA binding activities. <i>Biochemical Pharmacology</i> , 1994 , 48, 1583-91	6	8
44	First-trimester human trophoblast is class II major histocompatibility complex mRNA+/antigen. <i>Human Immunology</i> , 1994 , 39, 281-9	2.3	6
43	Methylation state of the human HLA-DRA gene in T-lymphocytes and B-lymphocytes of transgenic mice. Lack of methylation at one 5RGGCGC site is not required for gene expression. <i>FEBS Journal</i> , 1993 , 218, 485-92		2
42	Antigenic modulation of metastatic breast and ovary carcinoma cells by intracavitary injection of IFN-alpha. <i>British Journal of Cancer</i> , 1992 , 66, 342-4	8.7	1
41	Production and characterization of murine mAbs to the extracellular domain of human neu oncogene product GP185HER2. <i>Hybridoma</i> , 1992 , 11, 519-27		29

40	Membrane compartmentalization of melanosomal gp75. <i>Journal of Investigative Dermatology</i> , 1992 , 98, 340-2	4.3	6
39	Production and characterization of the murine monoclonal antibody 2G10 to a human T4-tyrosinase epitope. <i>Journal of Investigative Dermatology</i> , 1991 , 96, 446-51	4.3	33
38	Potential of growth suppression and modulation of the antigenic phenotype in human melanoma cells by the combination of recombinant human fibroblast and immune interferons. <i>Cancer Immunology, Immunotherapy</i> , 1991 , 32, 382-90	7.4	23
37	Tissue-specific expression of the HLA-DRA gene in transgenic mice. <i>Immunogenetics</i> , 1991 , 34, 385-91	3.2	9
36	Methylation state of the human HLA-DRA gene in transgenic mice. <i>Cytotechnology</i> , 1991 , 5, 55-6	2.2	
35	Transgenic mice mimic the methylation pattern of the human HLA-DR alpha gene. <i>Biochemical and Biophysical Research Communications</i> , 1991 , 175, 459-66	3.4	6
34	Distamycin inhibits the binding of a nuclear factor to the -278/-256 upstream sequence of the human HLA-DR alpha gene. <i>Biochemical Pharmacology</i> , 1991 , 41, 497-502	6	22
33	Methylation pattern of the HLA-DR alpha gene in human tissues. <i>International Journal of Immunogenetics</i> , 1990 , 17, 51-66		5
32	Quantitation of mRNA and protein products of the Ha-ras-1 proto-oncogene. <i>Breast Cancer Research and Treatment</i> , 1990 , 16, 287-9, 291	4.4	
31	Modulation of the antigenic phenotype of early-passage human melanoma cells derived from multiple autologous metastases by recombinant human leukocyte, fibroblast and immune interferon. <i>International Journal of Cancer</i> , 1990 , 46, 539-45	7.5	20
30	Human HLA-DR alpha gene: a rare oligonucleotide (GTATA) identifies an upstream sequence required for nuclear protein binding. <i>FEBS Letters</i> , 1990 , 268, 51-4	3.8	13
29	Methylation State of Cellular Genes and Oncogenes as a Marker of Malignancy in Human Carcinomas. <i>Tumori</i> , 1989 , 75, 321-328	1.7	1
28	mAb KUL/05 identifies a denaturation-resistant determinant shared by class II MHC products DR, DQ and DP. <i>International Journal of Immunogenetics</i> , 1989 , 16, 203-16		16
27	Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1989 , 86, 6719-23	11.5	112
26	CG Dinucleotides of class II MHC genes are mutation hot-spots. <i>Cytotechnology</i> , 1988 , 1, 133-8	2.2	2
25	Regulation of class II MHC gene expression by interferons: insights into the mechanism of action of interferon (review). <i>Anticancer Research</i> , 1988 , 8, 1153-61	2.3	46
24	Recombinant human IFN-gamma, but not IFN-alpha or IFN-beta, enhances MHC- and non-MHC-encoded glycoproteins by a protein synthesis-dependent mechanism. <i>Journal of Immunology</i> , 1988 , 140, 3073-81	5.3	30
23	Regulation of the expression of class II genes of the human major histocompatibility complex in tumor cells. <i>Annals of the New York Academy of Sciences</i> , 1987 , 511, 292-307	6.5	14

22	Multiple epitope recognition: an approach to improved radioimmunodetection of tumor-associated antigens. <i>International Journal of Cancer</i> , 1987 , 39, 729-36	7.5	19
21	Lack of correlation between hypomethylation and expression of the HLA-DR alpha gene. <i>European Journal of Immunology</i> , 1986 , 16, 365-9	6.1	18
20	Differential susceptibility to modulation by recombinant immune interferon of HLA-DR and -DQ antigens synthesized by melanoma COLO 38 cells. <i>Hybridoma</i> , 1986 , 5, 277-88		10
19	Effect of recombinant human fibroblast interferon and mezerein on growth, differentiation, immune interferon binding and tumor associated antigen expression in human melanoma cells. <i>Anticancer Research</i> , 1986 , 6, 765-74	2.3	14
18	Expression of tumor antigen correlated with metastatic potential of Lewis lung carcinoma and B16 melanoma clones in mice. <i>Cancer Research</i> , 1986 , 46, 5772-8	10.1	75
17	A third polypeptide associated with heavy and light chain subunits of class I HLA antigens in immune interferon-treated human melanoma cells. <i>European Journal of Immunology</i> , 1985 , 15, 946-51	6.1	15
16	Some evidence for the in vivo functional activation of suppressor T cells in asymptomatic patients with hemophilia A receiving Factor VIII concentrates. <i>Clinical Immunology and Immunopathology</i> , 1985 , 34, 27-38		11
15	Lymphoid stroma of Warthin [®] tumor: phenotypic analogies with gut-associated lymphoid tissue. <i>Clinical Immunology and Immunopathology</i> , 1985 , 34, 39-47		7
14	Modulation of tumor associated antigen expression and shedding by recombinant human leukocyte and fibroblast interferons 1985 , 31, 209-36		25
13	Analysis of the interaction between a human high molecular weight melanoma-associated antigen and the monoclonal antibodies to three distinct antigenic determinants. <i>Journal of Immunology</i> , 1985 , 135, 696-702	5.3	30
12	Heterogeneous distribution of actin, myosin, fibronectin and basement membrane antigens in primary and metastatic human breast cancer. <i>Virchows Archiv A, Pathological Anatomy and Histopathology</i> , 1984 , 405, 69-83		18
11	Modulation by recombinant DNA leukocyte (alpha) and fibroblast (beta) interferons of the expression and shedding of HLA- and tumor-associated antigens by human melanoma cells. <i>Journal of Immunology</i> , 1984 , 133, 1649-55	5.3	94
10	Isolation of viable melanoma cells from surgically removed lesions using dishes coated with monoclonal antibody to a high molecular weight melanoma associated antigen. <i>Journal of Immunological Methods</i> , 1983 , 62, 337-46	2.5	2
9	Antigenic profile of human melanoma cells. Analysis with monoclonal antibodies to histocompatibility antigens and to melanoma-associated antigens. <i>Journal of Cutaneous Pathology</i> , 1983 , 10, 225-37	1.7	19
8	The impact of monoclonal antibodies on the study of human malignant melanoma. <i>Journal of Cutaneous Pathology</i> , 1983 , 10, 514-28	1.7	24
7	Heterogeneity in the expression of HLA and tumor-associated antigens by surgically removed and cultured breast carcinoma cells. <i>Cancer Research</i> , 1983 , 43, 660-8	10.1	101
6	Antigenic heterogeneity of skin tumors of nonmelanocyte origin: analysis with monoclonal antibodies to tumor-associated antigens and to histocompatibility antigens. <i>Journal of the National Cancer Institute</i> , 1983 , 71, 439-47	9.7	32
5	Antigenic heterogeneity of surgically removed primary and autologous metastatic human melanoma lesions. <i>Journal of Immunology</i> , 1983 , 130, 1462-6	5.3	106

4	Analysis of the NIH workshop monoclonal antibodies to human melanoma antigens. <i>Hybridoma</i> , 1982 , 1, 473-82		16
3	Molecular heterogeneity and shedding of a high-molecular-mass melanoma-associated antigen identified with monoclonal antibodies. <i>Clinical Chemistry</i> , 1982 , 28, 2347-50	5.5	5
2	Human melanoma-associated antigens identified with monoclonal antibodies. <i>Research in Clinic and Laboratory</i> , 1982 , 12, 517-38		5
1	Ontogeny of murine I-Ak antigens in tissue of nonlymphoid origin. <i>Immunogenetics</i> , 1981 , 14, 359-65	3.2	14